INI-43
Based on 1 publication(s) in Google Scholar
INI-43 is an inhibitor of Kpnβ1, interfering with the nuclear localization of Kpnβ1 and known Kpnβ1 cargo proteins, NFAT, NFκB, AP-1, and NFY. INI-43 can inhibit the proliferation of cancer cells, cause G2-M cell cycle arrest in cancer cells, and induce the intrinsic apoptosis pathway.
For research use only. We do not sell to patients.
- Purity: 99.28%
- CAS No.: 881046-01-1
- Formula: C22H23N7
- Molecular Weight:385.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) INI-43
MoreAll AP-1 Isoforms
More
Biological Activity
INI-43 (5 μM, 2h) pretreatment n HeLa and SiHa cell lines of cervical cancer can effectively reduce the nuclear accumulation and activity of NFκB, resulting in decreased expression of cyclin D1, c-Myc and XIAP, and impaired DNA repair ability. Make cells more sensitive to Cisplatin[2].
INI-43 (10, 15 μmol/L, 1.5, 3h) interferes with the entry of Kpnβ1, NFAT, p65 and NFY into the nucleus and induces apoptosis in HeLa cells. The IC50 value of INI-43 against HeLa cells is 9.3 μmol/L[3].
INI-43 (5, 10 μmol/L, 5 days) has different sensitivity to cancer cell lines (cervical and esophageal cancer) and non-cancer lines (DMB and FG0), and INI-43 can kill cancer cells and has no effect on non-cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CaSki, HeLa, Kyse30, WHCO6, DMB and FG0 cells
-
Concentration:5, 10 μmol/L
-
Incubation Time:5 days
-
Result:At a concentration of 10 μmol/L, in less than 24 hours, the activity of cancer cells was significantly reduced, and within 48 to 72 hours, the cells were completely dead.
-
Cell Line:HeLa cells
-
Concentration:10, 15 μmol/L
-
Incubation Time:1.5, 3h
-
Result:Prevented NFY from entering the nucleus.
Cytochrome C levels in mitochondria decreased, activating endogenous apoptotic pathways, and caspase-3/7 activity significantly increased.
-
Cell Line:HeLa and SiHa cells
-
Concentration:5 μM
-
Incubation Time:2h
-
Result:Has a synergistic effect with Cisplatin, can inhibit Kpnβ1, increase the stability of p53, reduce the nuclear localization of NFκB and its target expression in SiHa cells after Cisplatin treatment, and enhance the DNA damage after Cisplatin treatment.
-
Cell Line:HeLa cells
-
Concentration:10 μmol/L
-
Incubation Time:1.5, 3h
-
Result:Prevented p65 from entering the nucleus.
INI-43 (50 mg/kg, intrabitoneal injection, once every 2-3 days, for 3 to 4 weeks) can inhibit tumor growth in mouse tumor xenotransplantation model [3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:WHCO6 esophageal cancer or CaSki cervical cancer cells mouse xenografts models[3]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Significantly inhibited the growth of esophageal and neck tumors.
Chemical Information
-
CAS No. 881046-01-1
-
Appearance Solid
-
Molecular Weight 385.46
-
Formula C22H23N7
-
Color Light yellow to yellow
-
SMILES
NC1=C(C2=NC3=CC=CC=C3N=C2N1CCCN(C)C)C4=NC5=CC=CC=C5N4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 100 mg/mL (259.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.49 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. F J Stanfield, et al. The antiviral activity of caprochlorone. Proc Soc Exp Biol Med. 1967 May;125(1):297-303. [Content Brief]
[2]. Chi RA, et al. Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 2;21(1):106. [Content Brief]
[3]. van der Watt PJ, et al. Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic. Mol Cancer Ther. 2016 Apr;15(4):560-73. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5943 mL | 12.9715 mL | 25.9430 mL | 64.8576 mL |
| 5 mM | 0.5189 mL | 2.5943 mL | 5.1886 mL | 12.9715 mL | |
| 10 mM | 0.2594 mL | 1.2972 mL | 2.5943 mL | 6.4858 mL | |
| 15 mM | 0.1730 mL | 0.8648 mL | 1.7295 mL | 4.3238 mL | |
| 20 mM | 0.1297 mL | 0.6486 mL | 1.2972 mL | 3.2429 mL | |
| 25 mM | 0.1038 mL | 0.5189 mL | 1.0377 mL | 2.5943 mL | |
| 30 mM | 0.0865 mL | 0.4324 mL | 0.8648 mL | 2.1619 mL | |
| 40 mM | 0.0649 mL | 0.3243 mL | 0.6486 mL | 1.6214 mL | |
| 50 mM | 0.0519 mL | 0.2594 mL | 0.5189 mL | 1.2972 mL | |
| 60 mM | 0.0432 mL | 0.2162 mL | 0.4324 mL | 1.0810 mL | |
| 80 mM | 0.0324 mL | 0.1621 mL | 0.3243 mL | 0.8107 mL | |
| 100 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL | 0.6486 mL |
INI-43 Related Classifications
HY-121607 Related Classifications
Powered by Bioz